Day: December 21, 2018

Precision BioSciences Appoints Rare Disease Executive Shalini Sharp to Its Board of Directors

From Startup Precision Biosciences Link to Full Article: http://precisionbiosciences.com/precision-biosciences-appoints-rare-disease-executive-shalini-sharp-to-its-board-of-directors/ DURHAM, North Carolina, USA, December 19, 2018 – Precision BioSciences, a genome editing company dedicated to improving life, announced today that industry veteran Shalini Sharp has joined the company’s Board of Directors. An established business leader in the life sciences industry,

Lexington, Mass. – December 20, 2018 –

From Startup Kaleido Link to Full Article: https://kaleido.com/kaleido-biosciences-announces-appointment-of-new-members-to-its-board-of-directors/ Lexington, Mass. – December 20, 2018 – Kaleido Biosciences, a healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ, today announced the appointment of three new members to its Board of Directors: Bonnie Bassler, Ph.D., Chair,

Myovant Sciences to Present at the 37th Annual J.P. Morgan Healthcare Conference

From Startup Myovant Link to Full Article: http://investors.myovant.com/news-releases/2018/12-20-2018-133012290 BASEL, Switzerland, Dec. 20, 2018 /PRNewswire/ — Myovant Sciences (NYSE: MYOV), a leading clinical-stage biopharmaceutical company focused on women’s health and endocrine diseases, today announced that Lynn Seely, M.D., President and Chief Executive Officer of Myovant Sciences, will present at the 37th Annual J.P. Morgan

European Medicines Agency Grants Orphan Drug Designation for Xeris’ Investigational Ready-to-Use Glucagon for the Treatment of Non-Insulinoma Pancreatogenous Hypoglycaemia Syndrome (NIPHS)

From Startup Xeris Pharmaceuticals Link to Full Article: https://investors.xerispharma.com/news-releases/news-release-details/european-medicines-agency-grants-orphan-drug-designation-xeris CHICAGO–(BUSINESS WIRE)–Dec. 20, 2018– Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, announced today that it has received Orphan Medicinal Product designation from the European